infection
Conditions
Interventions
experimental group:Ceftazidime-avibactam 2.5 g q8h and aztreonam 2 g q8h were administered simultaneously by intravenous infusion over 3 hours (using separate intravenous lines or a Y-site connector).
Comparator group:Ceftazidime-avibactam 2.5 g q8h was administered as a 2-hour intravenous infusion, followed by aztreonam 2 g q8h as a 1-hour intravenous infusion.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with complicated intra-abdominal infection, hospital-acquired pneumonia, ventilator-associated pneumonia, complicated urinary tract infection, or bloodstream infection 2.Infections confirmed by genotypic testing to be caused by metallo-ß-lactamase–producing carbapenem-resistant Gram-negative bacteria, using next-generation sequencing or carbapenem resistance gene detection; 3. Patients treated with ceftazidime-avibactam in combination with aztreonam.
Exclusion criteria
Exclusion criteria: 1. Aged<=18 years 2.Known hypersensitivity to ceftazidime, avibactam, aztreonam, or any excipient; or a history of severe allergic reaction (e.g., anaphylactic shock, severe skin reactions) to any other ß-lactam antimicrobial (such as penicillins, monobactams, or carbapenems) 3. Pregnant or breastfeeding women 4.Individuals unable to comprehend or comply with the study protocol 5.Any other condition deemed by the investigator to be unsuitable for trial participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma Concentration;Microbial Culture and Antimicrobial Susceptibility Test Results; | — |
Secondary
| Measure | Time frame |
|---|---|
| 30-day all-cause mortality;Intensive care unit length of stay;Total hospital length of stay; | — |
Countries
China
Contacts
Public ContactZhou Jing
The First Affiliated Hospital with Nanjing Medical University
Outcome results
None listed